An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Top Cited Papers
- 8 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 27 (7), 1250-1261
- https://doi.org/10.1038/s41591-021-01398-3
Abstract
Inhibitors of the PD-1–PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological alterations that occur in human cancer tissue after PD-1 blockade. We developed and employed a patient-derived tumor fragment platform to dissect the early immunological response of human tumor tissue to ex vivo PD-1 blockade. We observed that the capacity of immune cells to be reactivated ex vivo was predictive of clinical response, and perturbation analyses identified tumor-resident T cells as a key component of this immunological response. In addition, through combined analysis of baseline properties and immune response capacity, we identified a new subgroup of infiltrated tumors that lacks the capacity to respond to PD-1 blockade. Finally, the baseline presence of tertiary lymphoid structures and their components correlated with the capacity of cancers to undergo intratumoral immune cell reactivation.Keywords
This publication has 49 references indexed in Scilit:
- Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung CancerClinical Cancer Research, 2020
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapyScience Translational Medicine, 2020
- Peripheral T cell expansion predicts tumour infiltration and clinical responseNature, 2020
- Targeted deletion of PD-1 in myeloid cells induces antitumor immunityScience Immunology, 2020
- Trends in clinical development for PD-1/PD-L1 inhibitorsNature Reviews Drug Discovery, 2019
- Clonal replacement of tumor-specific T cells following PD-1 blockadeNature Medicine, 2019
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanomaNature Medicine, 2019
- Organoid Modeling of the Tumor Immune MicroenvironmentCell, 2018
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaNature Medicine, 2018
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014